We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Amegakaryocytic Thrombocytopenia in Systemic Lupus Erythematosus

Paul F. Griner, MD; Leon W. Hoyer, MD
Arch Intern Med. 1970;125(2):328-332. doi:10.1001/archinte.1970.00310020134020.
Text Size: A A A
Published online


Thrombocytopenia is a common feature of systemic lupus erythematosus (SLE). It is generally regarded as a manifestation of increased platelet destruction.1-8 This conclusion is based upon the observation of normal to increased numbers of megakaryocytes on bone marrow examination, information from platelet survival and kinetic studies in patients with this disease,9 and a generally good response to treatment with steroids or splenectomy. The frequency of antibodies directed against tissue components in SLE offers a possible explanation for shortened platelet survival, although these antibodies have not been demonstrated in vitro. In striking contrast to the usual findings associated with thrombocytopenia in SLE are those we have recently observed in a young woman with this illness. Selective bone marrow aplasia with absence of megakaryocytes was documented in this instance. In addition, the survival of transfused platelets did not suggest immune destruction. To our knowledge, this observation has not been previously


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.